Welcome to our dedicated page for Burning Rock Biotech news (Ticker: BNR), a resource for investors and traders seeking the latest updates and insights on Burning Rock Biotech stock.
Burning Rock Biotech Limited (BNR) reports developments in next-generation sequencing technology for precision oncology. Its news commonly covers financial results, Form 20-F annual reporting, annual general meeting actions, ADS-related ownership announcements, and clinical or regulatory updates for NGS assays used in therapy selection, MRD assessment, companion diagnostics and cancer early detection.
Company updates reference products and technologies such as OncoScreen, CanCatch and ELSA-seq, including study publications, patent grants and companion-diagnostic approvals connected to precision oncology testing.
Burning Rock Biotech (NASDAQ: BNR) filed its Annual Report on Form 20-F on April 28, 2026, for the year ended December 31, 2025. The filing is available on the SEC website and the company investor site.
The Form 20-F includes the audited consolidated financial statements. Shareholders and ADS holders may request a free hard copy by mail or email to the company.
Burning Rock (NASDAQ: BNR) announced that founder, chairman and CEO Yusheng Han purchased 31,487 ADSs on April 2, 2026 for US$546,603.90 from the open market.
Combined with 41,246 ADSs bought in the prior post-earnings window, Mr. Han has acquired an aggregate of 72,733 ADSs for US$1,358,325.18 across two consecutive post-earnings windows, and may continue purchasing in compliance with applicable rules.
Burning Rock (NASDAQ: BNR) reported unaudited Q4 and full‑year 2025 results on March 12, 2026. 2025 revenue was RMB539.6 million (US$77.2M), up 4.6% YoY; Q4 revenue was RMB126.3 million (US$18.1M). Gross margin rose to 74.7% for 2025 and operating expenses fell 36.4% year-over-year.
Key operational updates include USPTO grant for ELSA-seq patent, CMDE priority review for OncoScreen BCMatch Tissue Kit, and MRD study presentation at Annals of Surgery.
Burning Rock (NASDAQ: BNR) announced on Jan 5, 2026 that its founder, chairman and CEO Yusheng Han purchased US$811,721.28 of the company’s ADSs from the open market.
The company said the purchases were executed in compliance with applicable rules, the company’s insider trading policy, and may be continued through open-market transactions, privately negotiated trades or block trades depending on market conditions. The announcement notes timing will follow Rule 10b-18 and Rule 10b5-1 requirements and company policy.
Burning Rock (NASDAQ: BNR) announced that all shareholder resolutions at its 2025 annual general meeting held on Dec. 22, 2025 were duly passed.
Passed resolutions include: ratification of Ernst & Young Hua Ming LLP as auditor for the fiscal year ending Dec. 31, 2025 with directors authorized to set auditor remuneration; re-election of Feng Deng and Licen Lisa Xu as directors; and authorization for directors to take actions necessary to implement these resolutions.
Burning Rock Biotech (NASDAQ: BNR) will hold its 2025 Annual General Meeting on December 23, 2025 at 10:30 a.m. local time at its Shanghai office: 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai.
The AGM agenda includes ratifying the appointment of Ernst & Young Hua Ming LLP as auditor for the year ending December 31, 2025, re-election of Feng Deng and Licen Lisa Xu as directors, and authorizing directors to take actions to effect those resolutions. The board recommends shareholders and ADS holders vote in favor.
The record date for shareholders entitled to notice is December 1, 2025 (New York time). ADS holders must instruct Citibank, N.A. to vote underlying Class A shares. Burning Rock filed its Form 20-F with audited financials for year ended December 31, 2024.
Burning Rock (NASDAQ: BNR) reported results for Q3 2025 ended September 30, 2025. Total revenue was RMB131.6 million (US$18.5 million), up 2.3% year‑over‑year. Pharma R&D revenue rose 68.6% to RMB42.0 million (US$5.9 million). Gross profit was RMB98.8 million (US$13.9 million) with gross margin improving to 75.1% from 71.4% (≈370 bps). Operating expenses declined 11.9% to RMB115.0 million (US$16.2 million). Net loss narrowed to RMB16.8 million (US$2.4 million) from RMB35.7 million a year earlier. Cash and equivalents were RMB467.0 million (US$65.6 million) as of September 30, 2025.
Business highlights: MHLW approved OncoGuide OncoScreen Plus CDx for AstraZeneca capivasertib in Japan; PROMISE and clinical study results presented in September 2025 showing improved multimodal detection sensitivity.
Burning Rock Biotech (NASDAQ: BNR) and Riken Genesis have received approval from Japan's MHLW for their OncoGuide™ OncoScreen™ Plus CDx System as a companion diagnostic for AstraZeneca's capivasertib in breast cancer treatment.
The CDx System is designed to detect PIK3CA, AKT1, and PTEN alterations in a single test, supporting treatment decisions for adult patients with unresectable or recurrent HR-positive, HER2-negative breast cancer who have progressed after endocrine therapy. The diagnostic will be used for patient selection for capivasertib in combination with fulvestrant.
Riken Genesis will proceed with insurance coverage preparations to ensure patient access, while Burning Rock is advancing the product's registration in China.
Burning Rock Biotech (NASDAQ: BNR), a precision oncology NGS technology company, reported its Q2 2025 financial results with total revenues of RMB148.5 million (US$20.7 million), representing a 9.6% year-over-year increase.
The company's performance showed mixed results across segments: in-hospital business grew 4.4% to RMB62.5 million, central laboratory business declined 16.2% to RMB40.9 million, while pharma R&D services surged 68.1% to RMB45.2 million. Gross margin improved to 72.8% from 70.4% year-over-year.
Operating expenses decreased significantly by 42.1% to RMB119.6 million due to budget control measures and headcount reduction. The company narrowed its net loss to RMB9.7 million from RMB108.0 million in the previous year.